8-K current report · filed Nov 12, 2026

Oncology Institute, Inc. (TOI) 8-K Current Report: November 12, 2026

Item 7.01Item EX-99.1TOI overview

Short answer

Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation furnished as Exhibit 99.1 for use in investor meetings.

Oncology Institute, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor presentation furnished as Exhibit 99.1 for use in investor meetings
  • Presentation may contain material updates on Starling Oncology’s strategy, pipeline, or outlook requiring review before investment decisions

Item EX-99.1 · Exhibit EX-99.1

  • Investor presentation outlines oncology value-based care model across capitation, fee-for-service, specialty pharmacy, and clinical services
  • FY2026 revenue guidance $650–660M, adjusted EBITDA $4–6M, and free cash flow $5–10M
  • 3Q26 revenue $169.8M, up 24% YoY, with adjusted EBITDA $3.4M versus $(3.5)M in 3Q25
  • Specialty pharmacy revenue $109M, up 44% YoY, with 24% gross margin
  • MLR 81%, down 400 basis points sequentially, while delegated contracts ramp and remain a key margin risk

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Oncology Institute, Inc. 8-K filings

Get the next TOI 8-K as it lands

Follow TOI for push alerts, or ask the research agent what this filing means.